JP2022528024A5 - - Google Patents

Info

Publication number
JP2022528024A5
JP2022528024A5 JP2021525181A JP2021525181A JP2022528024A5 JP 2022528024 A5 JP2022528024 A5 JP 2022528024A5 JP 2021525181 A JP2021525181 A JP 2021525181A JP 2021525181 A JP2021525181 A JP 2021525181A JP 2022528024 A5 JP2022528024 A5 JP 2022528024A5
Authority
JP
Japan
Prior art keywords
antigen
tumor
cells
binding domain
tag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525181A
Other languages
English (en)
Japanese (ja)
Other versions
JP7674243B2 (ja
JP2022528024A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/051189 external-priority patent/WO2020087116A1/en
Publication of JP2022528024A publication Critical patent/JP2022528024A/ja
Publication of JP2022528024A5 publication Critical patent/JP2022528024A5/ja
Priority to JP2025072427A priority Critical patent/JP2025129148A/ja
Application granted granted Critical
Publication of JP7674243B2 publication Critical patent/JP7674243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525181A 2018-10-30 2019-10-29 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用 Active JP7674243B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072427A JP2025129148A (ja) 2018-10-30 2025-04-24 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2018904117A AU2018904117A0 (en) 2018-10-30 Polypeptides and uses thereof
AU2018904117 2018-10-30
AU2019903255A AU2019903255A0 (en) 2019-09-04 Polypeptides and uses thereof
AU2019903255 2019-09-04
PCT/AU2019/051189 WO2020087116A1 (en) 2018-10-30 2019-10-29 Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072427A Division JP2025129148A (ja) 2018-10-30 2025-04-24 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2022528024A JP2022528024A (ja) 2022-06-08
JP2022528024A5 true JP2022528024A5 (cg-RX-API-DMAC7.html) 2022-11-10
JP7674243B2 JP7674243B2 (ja) 2025-05-09

Family

ID=70461795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525181A Active JP7674243B2 (ja) 2018-10-30 2019-10-29 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用
JP2025072427A Pending JP2025129148A (ja) 2018-10-30 2025-04-24 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072427A Pending JP2025129148A (ja) 2018-10-30 2025-04-24 Carを発現する免疫細胞に抗原提示細胞を係合させるための二重特異性ポリペプチド及びそれらの使用

Country Status (9)

Country Link
US (2) US11866504B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877417A4 (cg-RX-API-DMAC7.html)
JP (2) JP7674243B2 (cg-RX-API-DMAC7.html)
KR (1) KR102961312B1 (cg-RX-API-DMAC7.html)
CN (1) CN113195535A (cg-RX-API-DMAC7.html)
AU (2) AU2019370618C1 (cg-RX-API-DMAC7.html)
CA (1) CA3117079A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104180WA (cg-RX-API-DMAC7.html)
WO (1) WO2020087116A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364234A1 (en) * 2020-03-06 2023-11-16 Albert Einstein College Of Medicine Compositions and methods for chimeric antigen receptor (car)-modified cell modulation
CN116390941A (zh) * 2020-07-16 2023-07-04 南京传奇生物科技有限公司 多特异性嵌合抗原受体及其用途
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Cd20結合分子及びその使用
CA3262796A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific Polypeptides and Their Uses
EP4590710A1 (en) * 2022-09-20 2025-07-30 Currus Biologics Pty Ltd A method of rescuing exhausted immune cells
AU2023347073A1 (en) * 2022-09-20 2025-01-02 Currus Biologics Pty Ltd Anti-flag antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688035T3 (es) * 2014-08-29 2018-10-30 Gemoab Monoclonals Gmbh Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
CN104829730A (zh) * 2015-04-14 2015-08-12 苏静 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用
EP3295171A1 (en) 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and kits for labeling, detection and isolation of foxp3+ regulatory t cells, isolated population of foxp3+ regulatory t cells thus obtained and uses thereof
WO2017167350A1 (en) * 2016-03-30 2017-10-05 Horst Lindhofer Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
WO2017177337A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
BR112019000512A2 (pt) * 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
CA3050614A1 (en) * 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
CN107417792B (zh) 2017-08-29 2020-07-03 天津医科大学总医院 抗cd40-her2双特异性单链抗体及其在制备抗肿瘤药物中的应用
AU2019315440B2 (en) * 2018-07-30 2025-03-13 Angeles Therapeutics, Inc. Improving the efficacy and safety of adoptive cellular therapies

Similar Documents

Publication Publication Date Title
Iwahori Cytotoxic CD8+ lymphocytes in the tumor microenvironment
US20240325450A1 (en) Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same
Yu et al. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
CA3162930A1 (en) Recombinant polypeptides for programming extracellular vesicles
US12491201B2 (en) Maximizing T-cell memory and compositions and methods therefor
JP2018509163A5 (cg-RX-API-DMAC7.html)
JP2017514471A5 (cg-RX-API-DMAC7.html)
JP2024515319A5 (cg-RX-API-DMAC7.html)
Ghorashian et al. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor
Stefanidis et al. Combining SiRPα decoy–coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells
EP4242309A1 (en) Chimeric antigen receptor
EP4232566A1 (en) Chimeric activation receptors
JP2023503840A5 (cg-RX-API-DMAC7.html)
JP2022525927A5 (cg-RX-API-DMAC7.html)
CN120676960A (zh) 开发增强car t细胞的功能和/或持久性的car衔接分子平台
Jiang et al. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors
Kucharczyk et al. Adoptive T-cell therapy in sarcomas
JP2020537517A5 (cg-RX-API-DMAC7.html)
Fujii et al. NKT-Licensed In Vivo Dendritic Cell− Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment
Kang et al. Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide
CN114437229B (zh) 携带pd-1単链抗体且靶向egfr抗原的car t免疫细胞的制备及其用途
HK40090148A (en) Nkt-cell subset for in vivo persistence and therapeutic activity and ppropagation of same
KR20250089551A (ko) 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법
HK40117726A (en) Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same